SCHEMBL3520596

SCHEMBL3520596

Cc1cnc2c(C(=O)O)c(O)ccc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKMYT1 Q99640 2/20 0.39
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
JAK3 P52333 1/20 0.36
PDE10A Q9Y233 1/20 0.35
ALDH1A1 P00352 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 2/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP1A2 P05177 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.34
ADRA2A P08913 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3753207 0.87 PKMYT1 (0.40) PKMYT1CA12CA1CA2CA7
SCHEMBL3517219 0.81 CA12 (0.37) CA12CA1CA2CA7CA9
SCHEMBL3516662 0.81 EGLN3 (0.57) EGLN3
SCHEMBL3520395 0.78 TDP1 (0.47) PKMYT1CA12CA1CA2CA7
SCHEMBL3521287 0.77 ABL1 (0.45) PDE10ASMN1; SMN2KDM4EHPGDMAPK1
SCHEMBL3576722 0.76 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2POLBKDM4EHPGD
SCHEMBL3766998 0.74 CA12 (0.43) CA12CA1CA2CA7CA9
SCHEMBL3516187 0.74 HSD17B10 (0.46) ALDH1A1SMN1; SMN2POLBKDM4EHPGD
SCHEMBL3530024 0.74 HTT (0.51) JAK3ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL3520879 0.74 NPC1 (0.52) ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 PKMYT1 3313/4885CA12 3023/4885CA1 1813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.